All In Biotech

Drug Trial Radar · NCT06555419

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

An Open Label Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered Via the ThecaFlex DRx™ System (PIERRE-PK)

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Jan 16, 2025

Primary completion

Sep 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
Alcyone Therapeutics, Inc
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this PIERRE-PK study, researchers will learn how the body processes nusinersen when it is given through the ThecaFlex DRx™ System, compared to when nusinersen is given by lumbar puncture (LP). The ThecaFlex DRx system is an investigational implantable medical device developed by Alcyone Therapeutics, Inc. It consists of a catheter, which is a flexible tube, connected to a port which is placed under the skin. Alcyone Therapeutics, Inc. has an ongoing study called PIERRE to test the ThecaFlex DRx system. Participants with spinal muscular atrophy (SMA) in the PIERRE study may be enrolled in the PIERRE-PK study. The main goal of the PIERRE-PK study is to learn how the body processes nusinersen when given by the ThecaFlex DRx system compared to a lumbar puncture. The main questions researchers want to answer are: * What is the highest amount of nusinersen found in the blood after dosing? * How much nusinersen is found in the blood over the first 24 hours after dosing? The PIERRE-PK study will be done as follows: * Participants will be screened to check if they can join the study. The screening period will be up to 30 days for this study and may overlap with the PIERRE study. * Participants will join 1 of 2 groups based on their ongoing nusinersen treatment. One group will be receiving 12 mg doses of nusinersen. The other group will be receiving 28 mg doses of nusinersen. * Participants will first receive a dose of nusinersen by lumbar puncture. * The ThecaFlex DRx system will be implanted after the lumbar puncture, as part of the PIERRE study. * Participants will receive a dose of nusinersen by the ThecaFlex DRx system, as part of the PIERRE study. This dose will be a regular maintenance dose that happens about 4 months after their first dose in this study. * Researchers will take blood samples before and after each dose. The last blood sample will be taken 24 hours after the dose. * The total study duration for each participant in the PIERRE-PK study will be approximately 5 months. This period will overlap with the participant's first 5 months in the PIERRE study.

Conditions

  • Muscular Atrophy, Spinal

Interventions

  • NusinersenDrug

    Administered as specified in the treatment arm.

  • ThecaFlex DRx SystemDevice

    Implanted as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Concentration (Cmax) of Nusinersen Delivered via Standard LP and via ThecaFlex DRx SystemTime frame: Pre-dose and at multiple time points post-dose over 4 months
  2. Area Under the Plasma Concentration-Time Curve From Zero Time to 24 Hours After Intrathecal Administration (AUC0-24h) of Nusinersen Delivered via Standard LP and via ThecaFlex DRx SystemTime frame: Pre-dose and at multiple time points post-dose over 4 months

Locations

21 sites in 7 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center - Barrow Neurological Institute

    Phoenix, Arizona · Recruiting

  • Children's Hospital of Orange County

    Orange, California · Recruiting

  • Stanford University Medical Center | Department of Neurology_Palo Alto

    Palo Alto, California · Recruiting

  • Nemours Children's Hospital, Orlando

    Orlando, Florida · Recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts · Recruiting

  • Helen DeVos Children's Hospita

    Grand Rapids, Michigan · Recruiting

  • Milton S. Hershey Medical Center | Pennsylvania State University_Hershey

    Hershey, Pennsylvania · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Texas Childrens Hospital Houston

    Houston, Texas · Recruiting

  • Stacey Hall Developmental Pediatrics

    Charlottesville, Virginia · Recruiting

  • Children's Hospital of the King's Daughters_Norfolk

    Norfolk, Virginia · Recruiting

  • Hôpital Raymond Poincaré

    Garches, Hauts De Seine, France · Recruiting

  • Universitaetsklinikum Essen

    Essen, Germany · Recruiting

  • Fondazione Serena Onlus - Centro Clinico Nemo_Milano

    Milan, Italy · Withdrawn

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy · Withdrawn

  • Szpital Specjalistyczny im. L.Rydygiera w Krakowie

    Krakow, Poland · Recruiting

  • Instytut Centrum Zdrowia Matki Polki

    Lodz, Poland · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • Hospital Universitari i Politecnic La Fe_Valencia

    Valencia, Spain · Recruiting

  • Royal Hallamshire Hospital Neurology Department

    Sheffield, South Yorkshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.